Phibro Animal Health Corp. (PAHC) PT Lowered to $55 at JPMorgan

Fri, 28 Aug 2026 09:02:09 -0400

JPMorgan analyst Ekaterina Knyazkova lowered the price target on Phibro Animal Health Corp. (NASDAQ: PAHC) to $55.00 (from $58.00) while maintaining a Overweight rating.

Form 8-K PHIBRO ANIMAL HEALTH For: Aug 26

Wed, 26 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260826/26982235.html

Form 8-K PHIBRO ANIMAL HEALTH For: Aug 26

Wed, 26 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260826/26982235.html

Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance

Wed, 26 Aug 2026 16:22:50 -0400

Phibro Animal Health (NASDAQ: PAHC) reported Q4 EPS of $0.85, $0.13 better than the analyst estimate of $0.72. Revenue for the quarter came in at $396.7 million versus the consensus estimate of $382.51 million.

GUIDANCE:

Phibro Animal Health sees FY2027 EPS of $3.41-$3.59, versus the consensus of $3.07. Phibro Animal Health sees FY2027 revenue of $1.55-1.6 billion, versus the consensus of $1.49 billion.

For earnings history and earnings-related data on Phibro Animal Health (PAHC) click here.

Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance

Wed, 26 Aug 2026 16:22:50 -0400

GUIDANCE:

Phibro Animal Health sees FY2027 EPS of $3.41-$3.59, versus the consensus of $3.07. Phibro Animal Health sees FY2027 revenue of $1.55-1.6 billion, versus the consensus of $1.49 billion.

For earnings history and earnings-related data on Phibro Animal Health (PAHC) click here.

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027.

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Wed, 26 Aug 2026 16:20:00 -0400

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

– Net sales of $396.7 million, an increase of $18.1 million, or 5%

– Net income of $21.7 million, an increase of $4.5 million, or 26%

– Diluted earnings per share of $0.53, an increase of $0.11, or 26%

Form 10-K PHIBRO ANIMAL HEALTH For: Jun 30

Wed, 26 Aug 2026 16:15:00 -0400

http://archive.fast-edgar.com/20260826/A6B4A22D822259Z2222C2ZZZMJ5FZ2Z2D282

Filed on: August 26, 2026

Form 10-K PHIBRO ANIMAL HEALTH For: Jun 30

Wed, 26 Aug 2026 16:15:00 -0400

http://archive.fast-edgar.com/20260826/A6B4A22D822259Z2222C2ZZZMJ5FZ2Z2D282

Filed on: August 26, 2026

JPMorgan Reiterates Overweight Rating on Phibro Animal Health Corp. (PAHC) Ahead of Q4 Print

Tue, 25 Aug 2026 08:35:35 -0400

JPMorgan analyst Ekaterina Knyazkova reiterated an Overweight rating and $58.00 price target on Phibro Animal Health Corp. (NASDAQ: PAHC).

The analyst commented, "Ahead of PAHC 4Q results we wanted to share some quick thoughts on the story. Overall, we are expecting a solid update with healthy livestock market dynamics and execution supporting results and are at the higher end of PAHC’s guidance range for the year. And looking to 2027 we see a constructive setup for both revenue and earnings growth with the Brazil headwind (antibiotics regulatory change) more than offset by favorable livestock market dynamics, revenue synergies (from ZTS MFA

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results